Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 382

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 382
---
 continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available
to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance
that any alternative courses of action to finance the Company would be successful.

This requirement for
additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group and Parent Company’s
ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available
to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances,
we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared
on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to current liabilities.

| F-41 |

| 3 | Revenue |

Revenue from contracts
with customers

Geographical analysis
of revenue by destination of customer

| Schedule of revenue by geographical analysis |     |            |     |            |     |            |
|                                              |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Revenue:                                     |     |            |     |            |     |            |
| Belgium                                      |     |        381 |     |        699 |     |        578 |
|                                              |     |        381 |     |        699 |     |        578 |

All revenue came from
the sale of services in 2023, 2022 and 2021. It is derived entirely from the Group’s R&D collaboration agreements. It is recognised
over the contract term proportionate to the progress in overall satisfaction of the performance obligations.

| Schedule of performance obligations                                                       |     |                    |     |            |     |            |   |     |                         |   |     |            |   |     |            |   |
|                                                                                           |     | Contractual Assets |     |            |     |            |   |     | Contractual Liabilities |   |     |            |   |     |            |   |
|                                                                                           |     | 2023 £’000         |     | 2022 £’000 |     | 2021 £’000 |   |     |              2023 £’000 |   |     |